NT 201 is a medication being tested in this clinical trial to see if it can help reduce pain for people who have chronic neuropathic pain. This type of pain can happen after conditions like postherpetic neuralgia, which is pain following shingles, or after an injury to the nerves. The trial is looking at how well NT 201 works in decreasing the intensity of this pain when given as an injection under the skin. The goal is to find out if NT 201 can make a significant difference in reducing daily pain levels compared to not using the medication.

Postherpetic Neuralgia – Postherpetic neuralgia is a condition characterized by persistent nerve pain following an outbreak of shingles, which is caused by the varicella-zoster virus. The pain is typically localized to the area where the shingles rash appeared and can be severe and debilitating. It is a type of neuropathic pain, meaning it results from nerve damage or dysfunction. The pain can be described as burning, stabbing, or aching, and may be accompanied by increased sensitivity to touch or temperature changes. Over time, the intensity of the pain may fluctuate, but it often persists for months or even years after the initial shingles infection has resolved.

Peripheral Neuropathic Pain – Peripheral neuropathic pain arises from damage or dysfunction of the peripheral nerves, which are the nerves outside the brain and spinal cord. This type of pain can result from various causes, including physical injury, infections, or systemic diseases like diabetes. The pain is often described as burning, tingling, or shooting, and it may be accompanied by numbness or weakness in the affected area. It can affect any part of the body but is most commonly experienced in the hands and feet. The progression of peripheral neuropathic pain can vary, with some individuals experiencing a gradual increase in symptoms, while others may have sudden and severe episodes.